Is Neurocrine Biosciences, Inc. (NBIX) a Buy, Sell, or Hold?
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
$172.05 USD
$0.01 (0.01%)
- Volume
- 870.84K
- Average Volume
- 1.22M
- Market Capitalization
- $17.3B
- P/E Ratio
- 25.64
- Dividend Yield
- 0.00%
- Price Target
- $195.00
- Year High
- $181.18
- Year Low
- $122.14
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.93
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Kyle W. Gano |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | NBIX |
| CUSIP | 64125C109 |
| CIK | 0000914475 |
| Web | https://www.neurocrine.com |
| Phone | 858 617 7600 |
| Currency | USD |
| Employees | 2000 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.12 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.93 |
| Quick Ratio | 2.85 |
| Cash Ratio | 0.32 |
Sales & Book Value
| Annual Sales | $2.86B |
| Price / Sales | 5.58 |
| Cash Flow | 8.27 |
| Price / Cash Flow | 20.81 |
| Price / Book | 5.07 |
Price Target and Rating
| Average Stock Price Forecast | $195.00 |
| High Stock Price Forecast | $230.00 |
| Low Stock Price Forecast | $160.00 |
| Forecast Upside/Downside | -11.77% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 37 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $4.67 |
| Trailing P/E Ratio | 25.64 |
| PEG Ratio | 0.21 |
| P/E Growth | 0.21 |
| Net Income | $478.6M |
| Net Margin | 21.55% |
| Pretax Margin | 30.22% |
| Return on Equity | 21.64% |
| Return on Assets | 13.63% |
Financials Score
| AltmanZ Score | 8.82 |
| Piotroski Score | 5.00 |
| Working Capital | 1.6B |
| Total Assets | 4.91B |
| Ebit | 926M |
| Market Cap | 17.51B |
| Total Liabilities | 1.5B |
Poll Results
About Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to s ... evere pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
NVIDIA & 2 Best Earnings Growth Stocks to Buy for 2H 2026
2026-07-15 16:00:16
NVIDIA, Neurocrine and Ball screen well for earnings growth and rising estimates, highlighting stocks with improving profit expectations.
Can Neurocrine (NBIX) Run Higher on Rising Earnings Estimates?
2026-07-14 13:21:03
Neurocrine Biosciences (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX)
2026-07-10 13:46:04
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline
2026-07-10 11:58:48
Biopharmaceutical firm Neurocrine Biosciences, Inc. (NBIX) up over 35% in a year and 17% since outlier inflows in May.
2026-07-09 16:01:00
Conference Call and Webcast Scheduled for Thursday, July 30 SAN DIEGO, July 9, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m.
Why Crinetics Stock Soared 99% This Week
2026-07-09 13:29:39
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.
Neurocrine (NBIX) Upgraded to Strong Buy: What Does It Mean for the Stock?
2026-07-08 13:01:09
Neurocrine (NBIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Reasons Why Investors Should Consider Betting on Neurocrine Stock
2026-07-06 11:45:53
NBIX builds on Ingrezza's momentum with pipeline advances and the Soleno acquisition, strengthening its long-term neuroscience growth strategy.
Frequently Asked Questions
-
What is the current Neurocrine Biosciences, Inc. (NBIX) stock price?
-
Neurocrine Biosciences, Inc.(NASDAQ:NBIX) stock price is $172.05 in the last trading session. During the trading session, NBIX stock reached the peak price of $181.18 while $122.14 was the lowest point it dropped to. The percentage change in NBIX stock occurred in the recent session was 0.01% while the dollar amount for the price change in NBIX stock was $0.01.
-
NBIX's industry and sector of operation?
-
The NASDAQ listed NBIX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of NBIX?
-
Jude Onyia | Chief Scientific Officer
Eiry Wyn Roberts | Strategic Advisor
Lawrence Steinman | Co-Founder of Neurocrine
Sanjay Keswani MBBS | Chief Medical Officer
Wylie W. Vale | Co-Founder -
How many employees does NBIX have?
-
Number of NBIX employees currently stands at 2000. NBIX operates from 12780 El Camino Real, San Diego, CA 92130, US.
-
Link for NBIX official website?
-
Official Website of NBIX is: https://www.neurocrine.com
-
How do I contact NBIX?
-
NBIX could be contacted at phone #858 617 7600 and can also be accessed through its website. NBIX operates from 12780 El Camino Real, San Diego, CA 92130, US.
-
How many shares of NBIX are traded daily?
-
The average number of NBIX shares traded daily for last 3 months was 1.22M.
-
What is the market cap of NBIX currently?
-
The market value of NBIX currently stands at $17.3B with its latest stock price at $172.05